

# Epithelialâ€“Mesenchymal Transition Is Associated with Including Elevation of Inflammatory Signals and Multiple Adenocarcinoma

Clinical Cancer Research

22, 3630-3642

DOI: [10.1158/1078-0432.ccr-15-1434](https://doi.org/10.1158/1078-0432.ccr-15-1434)

Citation Report

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy. <i>Critical Reviews in Immunology</i> , 2016, 36, 329-347.   | 1.0 | 7         |
| 2  | Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. <i>Oncotarget</i> , 2016, 7, 75379-75393. | 0.8 | 27        |
| 3  | Prognostic significance of PLIN1 expression in human breast cancer. <i>Oncotarget</i> , 2016, 7, 54488-54502.   | 0.8 | 38        |
| 4  | Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. <i>Scientific Reports</i> , 2016, 6, 31726.   | 1.6 | 232       |
| 5  | Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 47.   | 6.9 | 271       |
| 6  | Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?. <i>Clinical Cancer Research</i> , 2016, 22, 3422-3424.  | 3.2 | 65        |
| 7  | Learning from PD-1 Resistance: New Combination Strategies. <i>Trends in Molecular Medicine</i> , 2016, 22, 448-451.   | 3.5 | 61        |
| 8  | Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5553-5563.   | 3.2 | 96        |
| 9  | Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. <i>Oncolmmunology</i> , 2016, 5, e1234570.  | 2.1 | 23        |
| 10 | Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 79-87.   | 0.9 | 108       |
| 11 | Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogenic primary and metastatic lung cancer: Implications for immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1213934.   | 2.1 | 65        |
| 12 | Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression. <i>Journal of Immunology</i> , 2016, 197, 691-698.  | 0.4 | 75        |
| 13 | Hypoxia: Signaling the Metastatic Cascade. <i>Trends in Cancer</i> , 2016, 2, 295-304.  | 3.8 | 155       |
| 14 | T cell exhaustion: from pathophysiological basics to tumor immunotherapy. <i>Cell Communication and Signaling</i> , 2017, 15, 1.  | 2.7 | 154       |
| 15 | Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma. <i>BJU International</i> , 2017, 120, 343-350.  | 1.3 | 7         |
| 16 | Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. <i>Oncolmmunology</i> , 2017, 6, e1271858.  | 2.1 | 61        |
| 17 | The Role of Epithelial-Mesenchymal Transition in Chronic Obstructive Pulmonary Disease. <i>Cells Tissues Organs</i> , 2017, 203, 99-104.  | 1.3 | 11        |
| 18 | Candidate immune biomarkers for radioimmunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 58-68.  | 3.3 | 14        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. <i>Cancer Immunology Research</i> , 2017, 5, 319-329.  | 1.6 | 25        |
| 20 | PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system. <i>Oncotarget</i> , 2017, 6, e1315488.                   | 2.1 | 68        |
| 21 | Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. <i>Lung Cancer</i> , 2017, 109, 1-8.  | 0.9 | 27        |
| 22 | The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3 <sup>+</sup> CD8 <sup>+</sup> tumor infiltrating lymphocyte subpopulations. <i>Oncotarget</i> , 2017, 6, e1323617. | 2.1 | 14        |
| 23 | Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2713-2722.                     | 3.2 | 91        |
| 24 | Histologic Transformation in NSCLC with PD-1 therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, e133-e134.   | 0.5 | 9         |
| 25 | The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1. <i>Clinical Cancer Research</i> , 2017, 23, 2921-2923.   | 3.2 | 5         |
| 26 | Integrative analysis of genomic sequencing data reveals higher prevalence of LRP1B mutations in lung adenocarcinoma patients with COPD. <i>Scientific Reports</i> , 2017, 7, 2121.                                   | 1.6 | 25        |
| 27 | B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2017, 23, 5202-5209.   | 3.2 | 99        |
| 28 | New insights into the role of EMT in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.   | 2.1 | 332       |
| 29 | Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 907-920.                  | 1.1 | 88        |
| 30 | MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. <i>Oncogene</i> , 2017, 36, 4037-4046.  | 2.6 | 101       |
| 31 | MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 117-122.                      | 3.3 | 62        |
| 32 | Pharmacological and immunological targeting of tumor mesenchymalization. , 2017, 170, 212-225.   |     | 14        |
| 33 | A conduit to metastasis: circulating tumor cell biology. <i>Genes and Development</i> , 2017, 31, 1827-1840.   | 2.7 | 330       |
| 34 | Tumor cell-associated immune checkpoint molecules " Drivers of malignancy and stemness. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 571-583.   | 3.3 | 54        |
| 35 | Epithelial-mesenchymal transition and inflammation at the site of the primary tumor. <i>Seminars in Cancer Biology</i> , 2017, 47, 177-184.  | 4.3 | 128       |
| 36 | PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer. <i>Cellular Physiology and Biochemistry</i> , 2017, 42, 2267-2280.  | 1.1 | 92        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling. <i>European Journal of Cancer</i> , 2017, 85, 95-105.                       | 1.3 | 26        |
| 38 | Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 133-141.   | 0.5 | 44        |
| 39 | The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. <i>Cell Reports</i> , 2017, 20, 854-867.   | 2.9 | 258       |
| 40 | A novel bifunctional anti-PD-L1/TGF- $\beta$ 2 Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. <i>Onc Immunology</i> , 2017, 6, e1349589.   | 2.1 | 137       |
| 41 | CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1449-1461.          | 2.0 | 69        |
| 42 | Pan-urolologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.   | 5.8 | 49        |
| 43 | A combination of anti-PD-L1 plus Lm-LLoE6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers. <i>Cancer Medicine</i> , 2017, 6, 2052-2062.   | 1.3 | 21        |
| 44 | De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology</i> , The, 2017, 18, e731-e741.   | 5.1 | 568       |
| 45 | C-reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer. <i>Oncology Letters</i> , 2017, 14, 7417-7424.   | 0.8 | 29        |
| 46 | Genomic mechanisms of transformation from chronic obstructive pulmonary disease to lung cancer. <i>Seminars in Cancer Biology</i> , 2017, 42, 52-59.   | 4.3 | 23        |
| 47 | Multiplatform-based molecular subtypes of non-small-cell lung cancer. <i>Oncogene</i> , 2017, 36, 1384-1393.   | 2.6 | 118       |
| 48 | Malignant inflammation in cutaneous T-cell lymphoma—a hostile takeover. <i>Seminars in Immunopathology</i> , 2017, 39, 269-282.  | 2.8 | 110       |
| 49 | Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. <i>Cancers</i> , 2017, 9, 101.  | 1.7 | 56        |
| 50 | Tri-methylation of H3K79 is decreased in TGF- $\beta$ 1-induced epithelial-to-mesenchymal transition in lung cancer. <i>Clinical Epigenetics</i> , 2017, 9, 80.  | 1.8 | 40        |
| 51 | Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer. <i>Cell &amp; Developmental Biology</i> , 2017, 06, .   | 0.3 | 30        |
| 52 | Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. <i>Oncotarget</i> , 2017, 8, 19310-19322. | 0.8 | 81        |
| 53 | The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1011-1022.              | 2.0 | 36        |
| 54 | Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). <i>Scientific Reports</i> , 2018, 8, 2918.   | 1.6 | 182       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. <i>Oncogene</i> , 2018, 37, 2079-2088.   | 2.6 | 50        |
| 56 | Overexpression of geranylgeranyl diphosphate synthase contributes to tumour metastasis and correlates with poor prognosis of lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2177-2189.                        | 1.6 | 22        |
| 57 | MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 205-215.   | 0.4 | 167       |
| 58 | Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.   | 1.9 | 23        |
| 59 | Next generation of immune checkpoint therapy in cancer: new developments and challenges. <i>Journal of Hematology and Oncology</i> , 2018, 11, 39.  | 6.9 | 597       |
| 60 | Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. <i>Immunity</i> , 2018, 48, 417-433.   | 6.6 | 416       |
| 61 | Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas. <i>Developmental Dynamics</i> , 2018, 247, 555-564.  | 0.8 | 96        |
| 62 | Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 193-199.  | 0.6 | 162       |
| 63 | Prospects for new lung cancer treatments that target EMT signaling. <i>Developmental Dynamics</i> , 2018, 247, 462-472.   | 0.8 | 94        |
| 64 | Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1376155.  | 2.1 | 34        |
| 65 | Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 1695-1701.   | 1.0 | 77        |
| 66 | Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, E560-E563.                | 0.6 | 24        |
| 67 | Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129.  |     | 95        |
| 68 | Transcriptomic analysis of hepatocellular carcinoma reveals molecular features of disease progression and tumor immune biology. <i>Npj Precision Oncology</i> , 2018, 2, 25.  | 2.3 | 36        |
| 69 | Cellular Phenotype Plasticity in Cancer Dormancy and Metastasis. <i>Frontiers in Oncology</i> , 2018, 8, 505.   | 1.3 | 28        |
| 70 | Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment. <i>Cancer Letters</i> , 2018, 439, 1-13.  | 3.2 | 6         |
| 71 | Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 2374.  | 2.2 | 150       |
| 72 | Epithelial-mesenchymal transition: Initiation by cues from chronic inflammatory tumor microenvironment and termination by anti-inflammatory compounds and specialized pro-resolving lipids. <i>Biochemical Pharmacology</i> , 2018, 158, 261-273. | 2.0 | 26        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. <i>Nature Communications</i> , 2018, 9, 3503.  | 5.8  | 224       |
| 74 | Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 269.   | 1.3  | 106       |
| 75 | How Tumor Cells Choose Between Epithelial-Mesenchymal Transition and Autophagy to Resist Stress—Therapeutic Implications. <i>Frontiers in Pharmacology</i> , 2018, 9, 714.                             | 1.6  | 13        |
| 76 | CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. <i>Cancer Discovery</i> , 2018, 8, 1156-1175.  | 7.7  | 323       |
| 77 | Inflammatory interferon activates HIF-1 $\alpha$ -mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 70. | 3.5  | 59        |
| 78 | PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. <i>Journal of Hematology and Oncology</i> , 2018, 11, 16.                   | 6.9  | 96        |
| 79 | Cancer stem cells: Regulation programs, immunological properties and immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 94-106.  | 4.3  | 100       |
| 80 | B7-H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4693-4700.                                   | 1.0  | 34        |
| 81 | The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 285-308.  | 1.7  | 47        |
| 82 | The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review. <i>Frontiers in Immunology</i> , 2019, 10, 2043.                               | 2.2  | 7         |
| 83 | Integrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma. <i>EBioMedicine</i> , 2019, 46, 105-118.              | 2.7  | 30        |
| 84 | Epithelial-to-mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy. <i>Thoracic Cancer</i> , 2019, 10, 1841-1845.                         | 0.8  | 9         |
| 85 | ResolvinD1 attenuates high-mobility group box 1-induced epithelial-to-mesenchymal transition in nasopharyngeal carcinoma cells. <i>Experimental Biology and Medicine</i> , 2019, 244, 1608-1618.       | 1.1  | 6         |
| 86 | Controversies around epithelial-mesenchymal plasticity in cancer metastasis. <i>Nature Reviews Cancer</i> , 2019, 19, 716-732.   | 12.8 | 294       |
| 87 | Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. <i>Nature Cell Biology</i> , 2019, 21, 1113-1126.                                    | 4.6  | 202       |
| 88 | Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-11.              | 0.6  | 19        |
| 89 | Quantifying Cancer Epithelial-Mesenchymal Plasticity and its Association with Stemness and Immune Response. <i>Journal of Clinical Medicine</i> , 2019, 8, 725.  | 1.0  | 63        |
| 90 | Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. <i>Cancer Letters</i> , 2019, 458, 13-20.  | 3.2  | 83        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 806. | 1.7 | 66        |
| 92  | The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance. <i>Cancers</i> , 2019, 11, 838.   | 1.7 | 160       |
| 93  | Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. <i>Cancers</i> , 2019, 11, 714.  | 1.7 | 79        |
| 94  | Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. , 2019, 7, 121.  |     | 71        |
| 95  | Contribution of Epithelial Plasticity to Therapy Resistance. <i>Journal of Clinical Medicine</i> , 2019, 8, 676.   | 1.0 | 42        |
| 96  | The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System. <i>Cells</i> , 2019, 8, 460.  | 1.8 | 68        |
| 97  | Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients. <i>Cancer Cell International</i> , 2019, 19, 101.                     | 1.8 | 49        |
| 98  | Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis. <i>Developmental Cell</i> , 2019, 49, 361-374.   | 3.1 | 629       |
| 99  | Mesenchymal stem cells: From regeneration to cancer. , 2019, 200, 42-54.   |     | 84        |
| 100 | Cellular Plasticity in Cancer. <i>Cancer Discovery</i> , 2019, 9, 837-851.   | 7.7 | 309       |
| 101 | Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways. <i>Cell Death and Disease</i> , 2019, 10, 261.                               | 2.7 | 52        |
| 102 | Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. <i>Cancers</i> , 2019, 11, 298.   | 1.7 | 10        |
| 103 | Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis. <i>Oncology Letters</i> , 2019, 17, 4550-4556.            | 0.8 | 7         |
| 104 | Context-dependent EMT programs in cancer metastasis. <i>Journal of Experimental Medicine</i> , 2019, 216, 1016-1026.   | 4.2 | 388       |
| 105 | Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?. <i>Cancers</i> , 2019, 11, 422.   | 1.7 | 45        |
| 106 | Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. <i>Immunotherapy</i> , 2019, 11, 577-584.                      | 1.0 | 18        |
| 107 | Reversal of Epithelialâ€“Mesenchymal Transition by Natural Anti-Inflammatory and Pro-Resolving Lipids. <i>Cancers</i> , 2019, 11, 1841.  | 1.7 | 15        |
| 108 | A stroma-corrected ZEB1 transcriptional signature is inversely associated with antitumor immune activity in breast cancer. <i>Scientific Reports</i> , 2019, 9, 17807.                                 | 1.6 | 17        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 109 | An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. <i>Nature Communications</i> , 2019, 10, 5499.   | 5.8  | 132       |
| 110 | Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.   | 2.6  | 26        |
| 111 | Mapping lung cancer epithelial-mesenchymal transition states and trajectories with single-cell resolution. <i>Nature Communications</i> , 2019, 10, 5587.  | 5.8  | 162       |
| 112 | Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2021, 274, e150-e159.   | 2.1  | 5         |
| 113 | Agonist of PPAR- $\beta$ Reduced Epithelial-Mesenchymal Transition in Eosinophilic Chronic Rhinosinusitis with Nasal Polyps via Inhibition of High Mobility Group Box1. <i>International Journal of Medical Sciences</i> , 2019, 16, 1631-1641.        | 1.1  | 20        |
| 114 | PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 1313-1325.   | 2.0  | 288       |
| 115 | Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. <i>Neoplasia</i> , 2019, 21, 185-196.  | 2.3  | 38        |
| 116 | PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates. <i>Stem Cell Reviews and Reports</i> , 2019, 15, 324-330.  | 5.6  | 19        |
| 117 | EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 29-39.  | 3.3  | 137       |
| 118 | New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. <i>Nature Reviews Molecular Cell Biology</i> , 2019, 20, 69-84.   | 16.1 | 2,319     |
| 119 | Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. <i>Cancer Letters</i> , 2020, 468, 72-81.   | 3.2  | 195       |
| 120 | Cell stemness, epithelial-to-mesenchymal transition, and immunoevasion: Intertwined aspects in cancer metastasis. <i>Seminars in Cancer Biology</i> , 2020, 60, 181-190.   | 4.3  | 26        |
| 121 | Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. <i>Lung Cancer</i> , 2020, 139, 1-8.   | 0.9  | 92        |
| 122 | Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 140-154.   | 4.3  | 66        |
| 123 | $\beta$ -Glutamyl cyclotransferase contributes to endometrial carcinoma malignant progression and upregulation of PD-L1 expression during activation of epithelial-mesenchymal transition. <i>International Immunopharmacology</i> , 2020, 81, 106039. | 1.7  | 1         |
| 124 | VEGFR2 Promotes Metastasis and PD-L2 Expression of Human Osteosarcoma Cells by Activating the STAT3 and RhoA-ROCK-LIMK2 Pathways. <i>Frontiers in Oncology</i> , 2020, 10, 543562.   | 1.3  | 22        |
| 125 | Emerging role of tumor cell plasticity in modifying therapeutic response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 228.  | 7.1  | 120       |
| 126 | Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. <i>Cell</i> , 2020, 183, 1962-1985.e31.   | 13.5 | 177       |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | New insights into the interaction of the immune system with non-small cell lung carcinomas. <i>Translational Lung Cancer Research</i> , 2020, 9, 2199-2213.   | 1.3  | 11        |
| 128 | Mesenchymal Characteristics and Predictive Biomarkers on Circulating Tumor Cells for Therapeutic Strategy. <i>Cancers</i> , 2020, 12, 3588.   | 1.7  | 9         |
| 129 | Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions. <i>Cells Tissues Organs</i> , 2022, 211, 91-109.   | 1.3  | 12        |
| 130 | Hypoxia-driven intratumor heterogeneity and immune evasion. <i>Cancer Letters</i> , 2020, 492, 1-10.  | 3.2  | 39        |
| 131 | Impact of programmed death-ligand 1 expression on the patients of stage IV non-small cell lung cancer harboring epidermal growth factor receptor mutation: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 1430-1437. | 0.8  | 2         |
| 132 | Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. <i>Nature Communications</i> , 2020, 11, 4520.   | 5.8  | 218       |
| 133 | Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 3801.   | 1.7  | 28        |
| 134 | The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1526-1526.                | 0.7  | 14        |
| 135 | Persistent Cancer Cells: The Deadly Survivors. <i>Cell</i> , 2020, 183, 860-874.  | 13.5 | 157       |
| 136 | &lt;p&gt;Mitofusin1 Is a Major Mediator in Glucose-Induced Epithelial-to-Mesenchymal Transition in Lung Adenocarcinoma Cells&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3511-3523.  | 1.0  | 7         |
| 137 | New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 71.   | 1.6  | 71        |
| 138 | miR-24-3p/KLF8 Signaling Axis Contributes to LUAD Metastasis by Regulating EMT. <i>Journal of Immunology Research</i> , 2020, 2020, 1-8.  | 0.9  | 14        |
| 139 | Hypoxia-induced epithelial to mesenchymal transition in cancer. <i>Cancer Letters</i> , 2020, 487, 10-20.   | 3.2  | 86        |
| 140 | Identification of a Hypoxia-Associated Signature for Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 647.   | 1.1  | 53        |
| 141 | How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy. <i>Cancer Research</i> , 2020, 80, 4037-4041.   | 0.4  | 25        |
| 142 | A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 123.  | 1.8  | 62        |
| 143 | Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1327-1336.   | 2.0  | 16        |
| 144 | Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance. <i>Cells</i> , 2020, 9, 428.   | 1.8  | 111       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. <i>Journal of Thoracic Oncology</i> , 2020, 15, 777-791.   | 0.5 | 94        |
| 146 | Chronic IL-1 $\beta$ -induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 377.                                  | 1.6 | 65        |
| 147 | Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. <i>Cells</i> , 2020, 9, 263.  | 1.8 | 43        |
| 148 | Nuclear-localized costimulatory molecule 4-1BBL promotes colon cancer cell proliferation and migration by regulating nuclear Gsk3 $\beta$ , and is linked to the poor outcomes associated with colon cancer. <i>Cell Cycle</i> , 2020, 19, 577-591. | 1.3 | 4         |
| 149 | Cell adhesion in cancer: Beyond the migration of single cells. <i>Journal of Biological Chemistry</i> , 2020, 295, 2495-2505.   | 1.6 | 346       |
| 150 | Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 1052.  | 1.7 | 8         |
| 151 | Simultaneous inhibition of CXCR1/2, TGF- $\beta$ 2, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. , 2020, 8, e000326.  |     | 54        |
| 152 | Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2021, 22, e415-e424.   | 1.1 | 10        |
| 153 | Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 281-289.  | 2.9 | 22        |
| 154 | A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 923-933.  | 2.0 | 52        |
| 155 | Direct and Indirect Regulators of Epithelial-to-Mesenchymal Transition-Mediated Immunosuppression in Breast Carcinomas. <i>Cancer Discovery</i> , 2021, 11, 1286-1305.  | 7.7 | 76        |
| 156 | PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nslc patients. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 453-461.  | 2.0 | 16        |
| 157 | Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. <i>Journal of Clinical Investigation</i> , 2021, 131, .   | 3.9 | 48        |
| 158 | Immune checkpoint molecules are regulated by transforming growth factor (TGF)- $\beta$ 1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. <i>International Journal of Medical Sciences</i> , 2021, 18, 2466-2479.          | 1.1 | 17        |
| 159 | Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens. <i>Heliyon</i> , 2021, 7, e05880.   | 1.4 | 3         |
| 160 | Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity?. <i>Oncolmmunology</i> , 2021, 10, 1974233.  | 2.1 | 13        |
| 161 | Epithelial-Mesenchymal Transition Inversely Associates With Immune Activity in Breast Cancer Tumour Immune Microenvironment. <i>SSRN Electronic Journal</i> , 0, , .  | 0.4 | 0         |
| 162 | The Blood Microenvironment Influences the Molecular Phenotypes of Circulating Tumor Cells in Head and Neck Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 885-893.   | 0.5 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 163 | To betray or to fight? The dual identity of the mitochondria in cancer. <i>Future Oncology</i> , 2021, 17, 723-743.   | 1.1 | 7         |
| 165 | The emerging role of estrogen related receptor $\pm$ in complications of non-small cell lung cancers (Review). <i>Oncology Letters</i> , 2021, 21, 258.   | 0.8 | 11        |
| 166 | Lung cancer and epithelial-mesenchymal transition. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 781-789.  | 0.4 | 20        |
| 167 | Single-cell RNA-sequencing analyses identify heterogeneity of CD8+ T cell subpopulations and novel therapy targets in melanoma. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 105-118.  | 2.0 | 23        |
| 168 | Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses. <i>International Journal of Cancer</i> , 2021, 149, 546-560.   | 2.3 | 18        |
| 169 | An IFN $\gamma$ /STAT1/JMJD3 Axis Induces ZEB1 Expression and Promotes Aggressiveness in Lung Adenocarcinoma. <i>Molecular Cancer Research</i> , 2021, 19, 1234-1246.   | 1.5 | 6         |
| 170 | Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2021, 27, 4669-4679.  | 3.2 | 138       |
| 171 | PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer. <i>JCI Insight</i> , 2021, 6, .   | 2.3 | 40        |
| 172 | Prognostic significance of galectin $\beta$ expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy. <i>Thoracic Cancer</i> , 2021, 12, 1570-1578.   | 0.8 | 5         |
| 173 | Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC. <i>Journal of Molecular Histology</i> , 2021, 52, 597-609.  | 1.0 | 16        |
| 174 | Depleting Tumor Cells Expressing Immune Checkpoint Ligands: A New Approach to Combat Cancer. <i>Cells</i> , 2021, 10, 872.  | 1.8 | 2         |
| 175 | Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 497-508.  | 0.4 | 5         |
| 176 | A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of subcutaneous durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDU $\beta$ 1, SUB $\beta$ urothelial DURvalumab injection $\beta$ 1 study): clinical trial protocol. <i>BJU International</i> , 2021, 128, 9-17. | 1.3 | 6         |
| 177 | Cancer drug resistance induced by EMT: novel therapeutic strategies. <i>Archives of Toxicology</i> , 2021, 95, 2279-2297.   | 1.9 | 92        |
| 178 | Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. <i>Nature Communications</i> , 2021, 12, 2606.  | 5.8 | 41        |
| 179 | PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. <i>Cell Reports</i> , 2021, 35, 109181.   | 2.9 | 27        |
| 180 | Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2191.   | 1.0 | 9         |
| 181 | Identification of Epithelial-Mesenchymal Transition-Related Prognostic lncRNAs Biomarkers Associated With Melanoma Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 679133.  | 1.8 | 10        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 182 | HHLA2 deficiency inhibits non- $\alpha$ 1 small cell lung cancer progression and THP- $\alpha$ 1 macrophage M2 polarization. <i>Cancer Medicine</i> , 2021, 10, 5256-5269.  | 1.3 | 19        |
| 183 | Exploring the Crosstalk between Inflammation and Epithelial-Mesenchymal Transition in Cancer. <i>Mediators of Inflammation</i> , 2021, 2021, 1-13.  | 1.4 | 46        |
| 184 | The Role of B and T Lymphocyte Attenuator in Respiratory System Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 635623.  | 2.2 | 10        |
| 185 | The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis. <i>Frontiers in Oncology</i> , 2021, 11, 683951. | 1.3 | 17        |
| 186 | The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. <i>Npj Precision Oncology</i> , 2021, 5, 56.   | 2.3 | 44        |
| 187 | Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e491.                            | 1.7 | 26        |
| 188 | Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 587862.  | 1.3 | 6         |
| 189 | Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188564.  | 3.3 | 15        |
| 190 | Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1503-1512.   | 1.5 | 38        |
| 191 | Mnt Represses Epithelial Identity To Promote Epithelial-to-Mesenchymal Transition. <i>Molecular and Cellular Biology</i> , 2021, 41, e0018321.  | 1.1 | 4         |
| 192 | Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2021, 27, 6749-6760.  | 3.2 | 39        |
| 193 | BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 682007.  | 1.3 | 29        |
| 194 | PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells. <i>Cells</i> , 2021, 10, 2366.  | 1.8 | 13        |
| 195 | Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. , 2021, 9, e002922.  |     | 19        |
| 196 | A novel immune-related ceRNA network that predicts prognosis and immunotherapy response in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1484-1484.   | 0.7 | 6         |
| 197 | Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications. <i>Cancers</i> , 2021, 13, 4641.  | 1.7 | 10        |
| 198 | PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022, 1869, 119144.                         | 1.9 | 11        |
| 199 | Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study. <i>Surgery Open Science</i> , 2021, 6, 10-14.   | 0.5 | 4         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 200 | Analysis of the role of METTL5 as a hub gene in lung adenocarcinoma based on a weighted gene co-expression network. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 6608-6619.                      | 1.0 | 6         |
| 201 | Spatiotemporal Changes in Checkpoint Molecule Expression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 167-200.   | 0.8 | 5         |
| 202 | Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 67-77.  | 3.2 | 71        |
| 203 | Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.   | 5.8 | 140       |
| 204 | Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2017, 29, 408-415.                           | 0.4 | 23        |
| 207 | Long non-coding RNA, HOTAIRM1, promotes glioma malignancy by forming a ceRNA network. <i>Aging</i> , 2019, 11, 6805-6838.   | 1.4 | 43        |
| 208 | An individualized transcriptional signature to predict the epithelial-mesenchymal transition based on relative expression ordering. <i>Aging</i> , 2020, 12, 13172-13186.                                       | 1.4 | 5         |
| 209 | Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. <i>Oncotarget</i> , 2017, 8, 23020-23032.                  | 0.8 | 33        |
| 210 | Development of mesenchymal subtype gene signature for clinical application in gastric cancer. <i>Oncotarget</i> , 2017, 8, 66305-66315.   | 0.8 | 23        |
| 211 | Transforming growth factor $\beta$ -induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer. <i>Oncotarget</i> , 2019, 10, 810-824.                         | 0.8 | 22        |
| 212 | Tumor mutational burden in lung cancer: a systematic literature review. <i>Oncotarget</i> , 2019, 10, 6604-6622.  | 0.8 | 72        |
| 213 | Epithelial-mesenchymal transition: role in cancer progression and the perspectives of antitumor treatment. <i>Acta Naturae</i> , 2020, 12, 4-23.  | 1.7 | 12        |
| 214 | Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7139. | 1.8 | 33        |
| 215 | Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma. <i>Oncology Research</i> , 2020, 28, 561-578.  | 0.6 | 13        |
| 216 | miR-205 suppresses cell migration, invasion and EMT of colon cancer by targeting mouse double minute 4. <i>Molecular Medicine Reports</i> , 2020, 22, 633-642.  | 1.1 | 9         |
| 217 | EMT-related gene expression is positively correlated with immunity and may be derived from stromal cells in osteosarcoma. <i>PeerJ</i> , 2020, 8, e8489.  | 0.9 | 10        |
| 218 | miR-328-3p promotes migration and invasion by targeting H2AFX in head and neck squamous cell carcinoma. <i>Journal of Cancer</i> , 2021, 12, 6519-6530.   | 1.2 | 5         |
| 219 | Expression of PD1 and BTLA on the CD8+ T Cell and $\gamma\delta$ T Cell Subsets in Peripheral Blood of Non-Small Cell Lung Cancer Patients. <i>Chinese Medical Sciences Journal</i> , 2019, 34, 267.            | 0.2 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 220 | Novel Methods to Overcome Acquired Resistance to Immunotherapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 97-129.  | 0.1 | 0         |
| 224 | Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. American Journal of Cancer Research, 2019, 9, 800-815.  | 1.4 | 17        |
| 225 | The emerging role of circulating tumor cells in cancer management. American Journal of Translational Research (discontinued), 2020, 12, 332-342.  | 0.0 | 5         |
| 226 | Astragalus polysaccharides reverse gefitinib resistance by inhibiting mesenchymal transformation in lung adenocarcinoma cells. American Journal of Translational Research (discontinued), 2020, 12, 1640-1657.                                | 0.0 | 0         |
| 227 | Eradication of CSCs: the roadmap for curing cancer. Oncoscience, 2020, 7, 70-72.  | 0.9 | 0         |
| 228 | Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer. Endocrine Connections, 2020, 9, 1028-1041.   | 0.8 | 3         |
| 229 | Discovery of tumor immune infiltration-related snoRNAs for predicting tumor immune microenvironment status and prognosis in lung adenocarcinoma. Computational and Structural Biotechnology Journal, 2021, 19, 6386-6399.                     | 1.9 | 7         |
| 230 | Long noncoding TMPO antisense RNA 1 promotes hepatocellular carcinoma proliferation and epithelial-mesenchymal transition by targeting the microRNA-126-3p/LRP6/ $\beta$ -catenin axis. Annals of Translational Medicine, 2021, 9, 1679-1679. | 0.7 | 5         |
| 231 | The Epithelial-Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment. Cancers, 2021, 13, 5905.                        | 1.7 | 9         |
| 232 | Tumor metastasis: Mechanistic insights and therapeutic interventions. MedComm, 2021, 2, 587-617.  | 3.1 | 42        |
| 233 | Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma. Translational Oncology, 2022, 17, 101317.   | 1.7 | 12        |
| 234 | Eradication of CSCs: the roadmap for curing cancer. Oncoscience, 2020, 7, 70-72.  | 0.9 | 0         |
| 235 | Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer. Endocrine Connections, 2020, 9, 1028-1041.   | 0.8 | 9         |
| 236 | Pan-Cancer Analysis Shows Enrichment of Macrophages, Overexpression of Checkpoint Molecules, Inhibitory Cytokines, and Immune Exhaustion Signatures in EMT-High Tumors. Frontiers in Oncology, 2021, 11, 793881.                              | 1.3 | 12        |
| 237 | Transcriptional control of a collagen deposition and adhesion process that promotes lung adenocarcinoma growth and metastasis. JCI Insight, 2022, 7, .  | 2.3 | 12        |
| 238 | Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment. Cancers, 2022, 14, 539.  | 1.7 | 8         |
| 239 | Downregulation of SLC27A6 by DNA Hypermethylation Promotes Proliferation but Suppresses Metastasis of Nasopharyngeal Carcinoma Through Modulating Lipid Metabolism. Frontiers in Oncology, 2021, 11, 780410.                                  | 1.3 | 10        |
| 240 | Identification of Key Pathways and Genes Related to Immunotherapy Resistance of LUAD Based on WGCNA Analysis. Frontiers in Oncology, 2021, 11, 814014.  | 1.3 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 241 | Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders. , 2022, 10, e004034.  |     | 14        |
| 243 | Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer. Scientific Reports, 2022, 12, 2295.   | 1.6 | 8         |
| 244 | Circulating tumor cell methylation profiles reveal the classification and evolution of non-small cell lung cancer. Translational Lung Cancer Research, 2022, 11, 224-237.                               | 1.3 | 7         |
| 245 | ALDH3A1 overexpression in OSCC inhibits inflammation via phospho-Ser727 at STAT3 in tumor-associated macrophages. Oral Diseases, 2023, 29, 1513-1524.   | 1.5 | 6         |
| 246 | Epigenetic Activation of lncRNA MIR155HG Mediated by Promoter Hypomethylation and SP1 is Correlated with Immune Infiltration in Glioma. OncoTargets and Therapy, 2022, Volume 15, 219-235.              | 1.0 | 8         |
| 247 | Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma. Frontiers in Immunology, 2022, 13, 873116.   | 2.2 | 12        |
| 248 | Revealing the contribution of somatic gene mutations to shaping tumor immune microenvironment. Briefings in Bioinformatics, 2022, 23, .   | 3.2 | 6         |
| 250 | An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango. Clinical and Translational Oncology, 2022, 24, 1661-1672.                       | 1.2 | 3         |
| 251 | New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis. , 2022, 10, e003765.  |     | 10        |
| 252 | CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. Clinical and Translational Medicine, 2022, 12, e794. | 1.7 | 13        |
| 253 | Old and New Players of Inflammation and Their Relationship With Cancer Development. Frontiers in Oncology, 2021, 11, 722999.  | 1.3 | 14        |
| 254 | The pattern of alternative splicing in lung adenocarcinoma shows novel events correlated with tumorigenesis and immune microenvironment. BMC Pulmonary Medicine, 2021, 21, 400.                         | 0.8 | 0         |
| 255 | ZO-1 Intracellular Localization Organizes Immune Response in Non-Small Cell Lung Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 749364.  | 1.8 | 7         |
| 256 | Chamaejasmenin B, an Inhibitor for Metastatic Outgrowth, Reversed M2-Dominant Macrophage Polarization in Breast Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 774230.                      | 2.2 | 1         |
| 257 | Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients. Cancers, 2021, 13, 6225.  | 1.7 | 8         |
| 258 | Identification of an epithelial-mesenchymal transition-related lncRNA prognostic signature for patients with glioblastoma. Scientific Reports, 2021, 11, 23694.   | 1.6 | 11        |
| 259 | Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors. Frontiers in Genetics, 2022, 13, 864612.  | 1.1 | 22        |
| 260 | Network Pharmacology and Comparative Transcriptome Reveals Biotargets and Mechanisms of Curcumol Treating Lung Adenocarcinoma Patients With COVID-19. Frontiers in Nutrition, 2022, 9, 870370.          | 1.6 | 13        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 264 | Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice. <i>Journal of Breast Cancer</i> , 0, 25, .   | 0.8 | 2         |
| 265 | HOXC6 impacts epithelial-mesenchymal transition and the immune microenvironment through gene transcription in gliomas. <i>Cancer Cell International</i> , 2022, 22, 170.  | 1.8 | 6         |
| 267 | Autoimmunity and Cancer—Two Sides of the Same Coin. <i>Frontiers in Immunology</i> , 2022, 13, .  | 2.2 | 16        |
| 268 | Tumour budding is a novel marker in breast cancer: the clinical application and future prospects. <i>Annals of Medicine</i> , 2022, 54, 1303-1312.  | 1.5 | 15        |
| 269 | Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 169, 106-122.   | 1.3 | 12        |
| 270 | Epithelial-to-mesenchymal transition hinders interferon- $\gamma$ -dependent immunosurveillance in lung cancer cells. <i>Cancer Letters</i> , 2022, 539, 215712.  | 3.2 | 18        |
| 271 | CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT. <i>Journal of Cellular Biochemistry</i> , 2022, , .  | 1.2 | 3         |
| 272 | Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .          | 0.7 | 6         |
| 273 | Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients. <i>Frontiers in Medicine</i> , 2022, 9, . | 1.2 | 4         |
| 274 | The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8 <sup>+</sup> cytotoxic T-cell response. <i>Genes and Development</i> , 2022, 36, 582-600.         | 2.7 | 9         |
| 275 | High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration. <i>Journal of Immunology Research</i> , 2022, 2022, 1-28.               | 0.9 | 7         |
| 276 | Five EMT-related genes signature predicts overall survival and immune environment in microsatellite instability-high gastric cancer. <i>Cancer Medicine</i> , 2023, 12, 2075-2088.  | 1.3 | 8         |
| 277 | Cell Trajectory-Related Genes of Lung Adenocarcinoma Predict Tumor Immune Microenvironment and Prognosis of Patients. <i>Frontiers in Oncology</i> , 0, 12, .   | 1.3 | 8         |
| 278 | Comprehensive Analysis of Immune-Related Metabolic Genes in Lung Adenocarcinoma. <i>Frontiers in Endocrinology</i> , 0, 13, .   | 1.5 | 1         |
| 279 | Identification of metastasis-related long non-coding RNAs in lung cancer through a novel tumor mesenchymal score. <i>Pathology Research and Practice</i> , 2022, , 154018.  | 1.0 | 2         |
| 280 | PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway. <i>Scientific Reports</i> , 2022, 12, .  | 1.6 | 18        |
| 281 | Identification of EMT-Related Genes and Prognostic Signature With Significant Implications on Biological Properties and Oncology Treatment of Lower Grade Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .      | 1.8 | 1         |
| 282 | PD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition. <i>American Journal of Clinical Pathology</i> , 2022, 158, 506-515.                         | 0.4 | 4         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 283 | A complex epigenome-splicing crosstalk governs epithelial-to-mesenchymal transition in metastasis and brain development. <i>Nature Cell Biology</i> , 2022, 24, 1265-1277.   | 4.6 | 11        |
| 284 | MiR-192/pRB1/NF- $\kappa$ B/p65 signaling axis promotes IL-10 secretion during gastric cancer EMT to induce Treg cell differentiation in the tumour microenvironment. <i>Clinical and Translational Medicine</i> , 2022, 12, . | 1.7 | 11        |
| 285 | Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer. , 2022, 10, e004757.                                |     | 15        |
| 286 | Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. <i>Lung Cancer</i> , 2022, 172, 19-28.  | 0.9 | 9         |
| 287 | The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. <i>Journal of Hematology and Oncology</i> , 2022, 15, .  | 6.9 | 160       |
| 288 | Decoding the associations between cell functional states in head and neck cancer based on single-cell transcriptome. <i>Oral Oncology</i> , 2022, 134, 106110.   | 0.8 | 1         |
| 289 | Epithelial-Mesenchymal Transition in Gastrointestinal Cancer: From a Basic to a Clinical Approach. , 2022, , 45-67.  |     | 0         |
| 290 | Proteomics and liquid biopsy characterization of human EMT-related metastasis in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .  | 1.3 | 6         |
| 291 | Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment. <i>Cancers</i> , 2022, 14, 4465.   | 1.7 | 0         |
| 292 | Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113906.   | 2.5 | 36        |
| 293 | Transcriptional Profiling Reveals Mesenchymal Subtypes of Small Cell Lung Cancer with Activation of the Epithelial-to-Mesenchymal Transition and Worse Clinical Outcomes. <i>Cancers</i> , 2022, 14, 5600.                     | 1.7 | 1         |
| 294 | The mechanism of lncRNAs in the crosstalk between epithelial-mesenchymal transition and tumor microenvironment for early colon adenocarcinoma based on molecular subtyping. <i>Frontiers in Genetics</i> , 0, 13, .            | 1.1 | 0         |
| 295 | Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease. <i>Advances in Cancer Biology Metastasis</i> , 2022, 6, 100073.  | 1.1 | 0         |
| 296 | Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. <i>Seminars in Cancer Biology</i> , 2023, 88, 46-66.   | 4.3 | 23        |
| 297 | Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. <i>Journal of Translational Medicine</i> , 2022, 20, .   | 1.8 | 4         |
| 298 | IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. <i>Clinical Cancer Research</i> , 2023, 29, 1292-1304.  | 3.2 | 15        |
| 299 | AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1290-1303.   | 2.8 | 3         |
| 300 | An epithelial-to-mesenchymal transition induced extracellular vesicle prognostic signature in non-small cell lung cancer. <i>Communications Biology</i> , 2023, 6, .   | 2.0 | 5         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 301 | A ruptured sarcomatoid hepatocellular carcinoma treated with combined immunotherapy. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 244-249.   | 0.4 | 4         |
| 303 | Ethacrynic acid suppresses B7-H4 expression involved in epithelial-mesenchymal transition of lung adenocarcinoma cells via inhibiting STAT3 pathway. <i>Biochemical Pharmacology</i> , 2023, 212, 115537.             | 2.0 | 0         |
| 304 | Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. <i>Molecular Cancer</i> , 2023, 22, .  | 7.9 | 29        |
| 305 | Osimertinib Induces the Opposite Effect of Proliferation and Migration in the Drug Resistance of EGFR-T790M Non-small Cell Lung Cancer Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 1309-1319. | 0.9 | 1         |
| 306 | Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. , 2023, 20, 318-340.  |     | 13        |
| 307 | PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer. , 2023, 40, .   |     | 4         |
| 308 | Genomic characteristics and clinical significance of CD56+ circulating tumor cells in small cell lung cancer. <i>Scientific Reports</i> , 2023, 13, .   | 1.6 | 0         |
| 309 | Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .   | 7.1 | 27        |
| 310 | Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. <i>Molecular Cancer</i> , 2023, 22, .   | 7.9 | 18        |
| 311 | High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .   | 1.3 | 2         |
| 321 | Epithelial-Mesenchymal Plasticity: A Link Between Inflammation and Cancer Metastasis. , 2023, , 1-22.   |     | 0         |
| 335 | Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer. <i>Discover Oncology</i> , 2023, 14, .   | 0.8 | 0         |